ValuEngine lowered shares of Immune Design Corp. (NASDAQ:IMDZ) from a hold rating to a sell rating in a research report released on Monday.

Several other equities research analysts also recently issued reports on IMDZ. BidaskClub downgraded shares of Immune Design Corp. from a strong-buy rating to a buy rating in a research report on Saturday, August 5th. Royal Bank Of Canada began coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an outperform rating and a $20.00 price objective for the company. Jefferies Group LLC restated a buy rating and set a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. Cowen and Company restated a buy rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a hold rating to a buy rating and set a $11.00 price objective for the company in a research report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $16.33.

Immune Design Corp. (IMDZ) traded down 0.18% during trading on Monday, hitting $10.83. The stock had a trading volume of 15,258 shares. The company’s market capitalization is $277.45 million. The stock has a 50 day moving average price of $9.82 and a 200 day moving average price of $8.36. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. Equities research analysts forecast that Immune Design Corp. will post ($2.34) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “ValuEngine Lowers Immune Design Corp. (IMDZ) to Sell” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/05/valuengine-lowers-immune-design-corp-imdz-to-sell.html.

In related news, Director Lewis W. Coleman acquired 10,000 shares of the business’s stock in a transaction on Monday, July 10th. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $90,000.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $360,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lewis W. Coleman acquired 8,000 shares of the business’s stock in a transaction on Friday, July 7th. The shares were bought at an average price of $9.27 per share, with a total value of $74,160.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $370,800. The disclosure for this purchase can be found here. Insiders have acquired 40,000 shares of company stock valued at $369,760 over the last 90 days. Company insiders own 20.70% of the company’s stock.

A number of hedge funds have recently modified their holdings of IMDZ. California State Teachers Retirement System increased its holdings in shares of Immune Design Corp. by 8.3% during the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 2,300 shares during the period. Sectoral Asset Management Inc bought a new position in shares of Immune Design Corp. during the second quarter worth approximately $1,641,000. Goldman Sachs Group Inc. bought a new position in shares of Immune Design Corp. during the second quarter worth approximately $291,000. Numeric Investors LLC bought a new position in shares of Immune Design Corp. during the second quarter worth approximately $1,641,000. Finally, Bain Capital Public Equity Management LLC increased its holdings in shares of Immune Design Corp. by 393.1% during the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock worth $3,797,000 after purchasing an additional 310,433 shares during the period. Hedge funds and other institutional investors own 51.46% of the company’s stock.

About Immune Design Corp.

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.